Nolomirole
Nolomirole (CHF 1035) is an orally active and selective DA2 dopaminergic receptor/α2-adrenoceptor agonist. Nolomirole attenuates the heart failure signs in the Monocrotaline -induced congestive heart failure model. Nolomirole increases cardiac output[1][2][3][4].
Product Specifications
CAS Number
90060-42-7
Product Name Alternative
CHF 1035 (free base)
UNSPSC
12352005
Target
Adrenergic Receptor; Dopamine Receptor
Related Pathways
GPCR/G Protein; Neuronal Signaling
Field of Research
Cardiovascular Disease
Smiles
CC(C)C(OC1=C2C(CC(NC)CC2)=CC=C1OC(C(C)C)=O)=O
Molecular Formula
C19H27NO4
Molecular Weight
333.42
References & Citations
[1]1. Afzal M. Recent updates on novel therapeutic targets of cardiovascular diseases. Mol Cell Biochem. 2021 Jan; 476 (1) :145-155. |[2]2. Torp-Pedersen C, et al. A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. Eur J Heart Fail. 2008 Jan; 10 (1) :89-95. |[3]3. Tjeerdsma G, et al. Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure. Cardiovasc Drugs Ther. 2001 Mar; 15 (2) :139-45. |[4]4. Pasini E, et al. Effect of nolomirole on monocrotaline-induced heart failure. Pharmacol Res. 2004 Jan; 49 (1) :1-5.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
